- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02130323
Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix
Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
MATERIALS AND METHODS: A randomized controlled trial of patients with CIN 2-3 to receive either surgical excision with LEEP or CKC versus medical therapy with Imiquimod once weekly inserted vaginally for 16 weeks. Inclusion criteria are women age 21 years or older with confirmed histological diagnosis of CIN 2-3 with a normal endocervical curettage (ECC) if obtained and satisfactory colposcopy (the transformation zone of the cervix was completely visualized.) Exclusion criteria include positive CIN2-3 on ECC, presence of cancer, pregnancy or lactation, immune deficiency, hepatitis, or hypersensitivity to Imiquimod. Patients will be randomized to receive excision with LEEP/CKC or Imiquimod 250 mg (5%) cream (12.5 mg of active ingredient) inserted vaginally once a week for 16 weeks.
The primary outcome will be histological regression to CIN 1 or less. Secondary outcomes will be complete histological regression, high-risk Human Papilloma Virus (HPV) clearance, Clearance of HPV 16, 18/45, and patient tolerance of Imiquimod regimen. Follow up with repeat pap, HPV typing to include 16 and 18/45 subtyping, and colposcopy with directed cervical biopsy will be performed at 6 months post initiation of treatment. Patients unable to complete at least 8 treatments and miss two treatments consecutively will be considered failures and offered immediate LEEP. Those patients that complete 8 treatments of Imiquimod will be reevaluated 6 months from initiating treatment. Demographic information will be obtained to include age, gravidity and parity, smoking history, and contraceptive use.
Descriptive statistics will include numbers and rates of occurrence with confidence intervals of regression, pre, and post-treatment HPV including HPV 16 and 18/45 typing, and adverse effects. The assumed regression rate for the LEEP arm varies within studies. We are choosing a conservative estimate of 85% regression rate from CIN2+ to CIN1 or less. More recently in a 2014 publication in the Journal of Virology (Author Antonio Frega, Journal of Clinical Virology 60 (2014) 39-43) 13% of the LEEP patients out of 475 had residual disease after LEEP. In this study they excluded the 10% of patients that had had positive margins on their LEEP specimen. We are not excluding them as this is intent to treat study. For Imiquimod the Grimm study found a 73.3% regression rate with those treated with the active ingredient. A non-inferiority-type design for two proportions using differences is used in which the difference between treatments is defined as medical treatment being preferable if the regression rate is not more than 15% below that of the excisional treatment. Comparison of the regression rates of the two treatments will be made by a non-inferiority Fisher's exact test.
Required sample size was assessed using the PASS software of the NCSS statistical package. Using power = 0.80 and alpha = 0.05, a power analysis predicts the need for 68 patients per arm for 136. Post-treatment HPV rates will be compared similarly. We will recruit 75 patients to each arm to buffer for a dropout rate.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92134-5000
- Naval Medical Center San Diego
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy women older than age 21, military or civilian
- Negative pregnancy test results
- Confirmed CIN 2-3 on cervical biopsy with a negative endocervical curettage (ECC) and satisfactory colposcopy visualizing the complete transformation zone of the cervix.
- The patient will be available and in the San Diego area for 6 months after enrollment to complete the clinic visits and follow up.
Exclusion Criteria:
- Positive CIN 2-3 on ECC
- Presence of cancer
- Pregnancy or lactation
- Immuno-compromised (systemic lupus erythematosus, kidney transplant)
- Hepatitis
- Hypersensitivity to Imiquimod
- Ulcerative colitis
- Crohn's disease
- Human Immunodeficiency virus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Loop Electrosurgical Excision Procedure
Excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP) or cold knife conization (CKC).
|
Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
Other Names:
|
Experimental: Imiquimod
Imiquimod 12.5mg intravaginally once weekly for 16 weeks
|
12.5mg (5%) once a week vaginally for 16 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Human Papillomavirus(HPV) Clearance
Time Frame: 6 months from treatment initiation
|
HPV clearance will be determined by pathology and HPV testing, followed by colposcopy. Descriptive statistics will include numbers and rates of occurrence with confidence intervals of regression, pre and post-treatment HPV including Human Papillomavirus type 16 (HPV16) and HPV 18/45 typing, and adverse effects. A non-inferiority type design is used in which the difference between treatments is defined as medical treatment being preferable if the regression rate is not more than 10% below that of the excisional treatment. Comparison of the regression rates of the two treatments will be made by a non-inferiority Fisher's exact test. |
6 months from treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evidence of local or systemic side effects of Imiquimod cream
Time Frame: Every 4 weeks after initiation of Imiquimod Arm for 16 weeks
|
Patients will be seen in dysplasia clinic at Naval Medical Center San Diego (NMCSD) every 4 weeks while in treatment to determine tolerability of the Imiquimod Arm.
Patients with significant symptoms will be asked to delay using Imiquimod until symptoms resolve before resuming.
Patients unable to complete at least 4 weeks of treatment (1 treatment per week), will be offered immediate LEEP or surveillance at the 6 month follow up.
|
Every 4 weeks after initiation of Imiquimod Arm for 16 weeks
|
Evidence of local or systemic side effects of Imiquimod cream
Time Frame: Daily after initiation of Imiquimod treatment Arm, up to 6 months after study initiation
|
Patients will be provided a daily phone number to a qualified nurse regarding any symptoms experienced while on the Imiquimod arm of the study.
Patients will be instructed to be evaluated in the Emergency Department after clinic hours if needed for up to 6 months after study initiation.
|
Daily after initiation of Imiquimod treatment Arm, up to 6 months after study initiation
|
Number of Participants with Serious and Non-Serious Adverse Events
Time Frame: Up to 6 months after study initiation
|
All reported Adverse Events will be captured on the Adverse Event report.
|
Up to 6 months after study initiation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Addie N Alkhas, MD, United States Naval Medical Center, San Diego
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMCSD.2014.0040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Intraepithelial Neoplasia
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States
-
Genexine, Inc.CompletedCervical Intraepithelial Neoplasia 3Korea, Republic of
-
Nykode Therapeutics ASATheradex; Vaccibody ASCompletedHigh Grade Cervical Intraepithelial NeoplasiaGermany
-
University of Alabama at BirminghamNational Cancer Institute (NCI)CompletedHigh-grade Cervical Intraepithelial NeoplasiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
Brookdale University Hospital Medical CenterUnknownCarcinoma in Situ of Uterine Cervix | Cervical Intraepithelial Neoplasias | High Grade Cervical Intraepithelial NeoplasiaUnited States
-
BioLeaders CorporationUnknownCervical Intraepithelial Neoplasia Grade 2/3Korea, Republic of
-
University Medical Centre MariborRecruitingCervical Intraepithelial Neoplasia Grade 2 | DNA MethylationSlovenia
-
Onconix, IncUnknownCervical Cancer | Cervical Intraepithelial Neoplasia III | Cervical Intraepithelial Neoplasia IIUnited States
Clinical Trials on Loop Electrosurgical Excision Procedure
-
Centre Hospitalier Universitaire, AmiensCompletedPregnancy Complications
-
Ontario Clinical Oncology Group (OCOG)Canadian Institutes of Health Research (CIHR)CompletedCervical Intraepithelial NeoplasiaCanada, Brazil
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCervical CancerUnited States, Canada
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionPeru, Malawi, South Africa, Zimbabwe, Haiti, Botswana, India
-
Ruhr University of BochumRecruiting
-
Instituto Nacional de Saúde, MozambiqueM.D. Anderson Cancer CenterNot yet recruitingHIV Infections | HPV Infection | CIN 2/3Mozambique
-
Oswaldo Cruz FoundationCompletedCervical Intraepithelial NeoplasiaBrazil
-
University of California, IrvineNational Cancer Institute (NCI)CompletedCervical Intraepithelial NeoplasiaUnited States
-
Tampere University HospitalHelsinki University Central Hospital; Oulu University Hospital; Kuopio University... and other collaboratorsNot yet recruitingCervical DysplasiaFinland
-
Oswaldo Cruz FoundationCompletedCervical Intraepithelial NeoplasiaBrazil